证券代码：600535 证券简称：天士力 编号：临 2024-049 号 天士力医药集团股份有限公司 关于公司获得美国 FDA 临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）收到美国食品药 品监督管理局（以下简称"FDA"）关于同意同种异体脂肪间充质基质细胞治疗 急性缺血性脑卒中的药物NR-20201注射液进行临床试验的函（IND编号：30788）。 现就相关情况公告如下： 一、药物基本情况 规格：1×106 cells/mL，50mL/袋 根据美国药品注册相关的法律法规要求，药物在获得临床试验资格后，尚需 开展临床试验并经美国FDA审批通过后方可生产上市，其过程与结果存在不确定 性。 生物医药产品具有高科技、高风险、高附加值的特点，新药研发以及产品从 研制、临床试验报批到投产的周期长、环节多，容易受到技术、审核等不确定因 素影响，未来产品市场竞争形势也将发生变化，公司将按相关国家有关规定积极 1 剂型：注射液 申请人：天士力医药集团股份有限公司 ...

天士力（600535.SH）2024 年三季报点评 [盈利预测与财务指标 Table_Forcast] 克服产品降价因素，中药板块营收仍稳健增长 2024 年 10 月 27 日 ➢ 事件：2024 年 10 月 25 日，公司发布 2024 年三季报。公司前三季度实现 营业收入64.63亿元，同比下滑1.66%；归母净利润8.42亿元，同比下滑18.41%； 扣非净利润 9.82 亿元，同比下滑 6.78%。归母净利润下滑主要系公司持有的金 融资产公允价值变动损失高于上年同期及部分产品降价毛利下降所致。 ➢ 费用率基本稳定，核心产品降价毛利率下降。公司 2024 年前三季度销售费 用率、管理费用率和研发费用率分别为 34.18%，3.76%和 8.74%，与去年同期 费用率基本相当。由于核心产品复方丹参滴丸集采降价，公司营收占比最大的心 脑血管治疗领域毛利率比去年同期下降 3.47 pct。 ➢ 中药板块营收仍稳健增长。2024 年前三季度，公司医药工业营收增长 2.18%，医药商业营收下滑 25.36%。医药工业分产品看，中药营收增长 0.51%， 化学制剂营收增长 11.08%，生物药营收增长 0.55 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a slight increase in revenue for the first three quarters of the year, with a focus on steady growth in its modern traditional Chinese medicine segment and significant recovery in its chemical preparations segment [1] Group 1: Financial Performance - The pharmaceutical industrial revenue for the first three quarters reached 5.737 billion yuan, a year-on-year increase of 2.18% [1] - The modern traditional Chinese medicine segment generated 4.578 billion yuan, with a growth of 0.51% year-on-year [1] - The cardiovascular segment saw a year-on-year growth of 3.54%, with core products showing positive growth [1] - The chemical preparations segment achieved revenue of 966 million yuan, marking an 11.08% increase, driven by rapid growth in the sales of water-lin-jia and a recovery in anti-tumor product sales [1] Group 2: Dividend and R&D Investment - The company announced a cash dividend of 0.70 yuan per 10 shares (before tax), bringing the total cash dividend per share to 0.33 yuan for the first three quarters of the year [1] - Research and development investment for the first three quarters amounted to 565 million yuan, showing a slight increase compared to the same period last year [1] Group 3: R&D Pipeline - The company has a pipeline of 25 products in modern traditional Chinese medicine research [1] - Two products, Pi Pa Qing Fei Yin and Wen Jing Tang, are in the production application stage, having passed drug registration and production site inspections [1] - Nineteen products are in clinical phases II and III, with several projects, including An Shen Di Wan and Qing Zhu Ke Li, having entered clinical phase III [1] - The company’s significant biopharmaceutical product, Pu You Ke, has expanded its indications from treating acute ST-segment elevation myocardial infarction to acute ischemic stroke, with the latest phase IIIc validation trial report submitted for production application [1]

Revenue and Profit Performance - Revenue for the third quarter was RMB 2.09 billion, a decrease of 4.06% compared to the same period last year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 179.89 million, a decrease of 44.67% year-on-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was RMB 6.46 billion, a decrease of 1.66% compared to the same period last year[2] - Cumulative net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period was RMB 325.12 million, a decrease of 18.41% year-on-year[2] - Total revenue for the first three quarters of 2024 was 6,462,559,794.57 RMB, a slight decrease from 6,571,392,090.82 RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 828,144,304.95 RMB, down from 1,000,105,317.73 RMB in the same period of 2023[18] - Revenue for the first three quarters of 2024 reached 4,324,188,522.33 RMB, up from 4,092,108,241.36 RMB in the same period last year[25] - Net profit for the first three quarters of 2024 was 871,685,138.46 RMB, down from 1,041,089,199.71 RMB in the same period last year[26] Profitability Factors - The decrease in net profit was mainly due to higher fair value losses on financial assets and lower gross margins from product price reductions[4] - Basic earnings per share for the third quarter were RMB 0.12, a decrease of 45.45% year-on-year[3] - Net profit attributable to shareholders of the parent company was 842,201,236.32 RMB, down from 1,032,219,095.72 RMB in the same period of 2023[18] - Basic earnings per share for the first three quarters of 2024 were 0.56 RMB, down from 0.69 RMB in the same period of 2023[19] Asset and Equity Changes - Total assets at the end of the reporting period were RMB 16.83 billion, an increase of 0.72% compared to the end of the previous year[3] - Shareholders' equity attributable to the listed company at the end of the reporting period was RMB 12.71 billion, an increase of 2.74% compared to the end of the previous year[3] - Tianshi Pharmaceutical Group's total current assets as of September 30, 2024, amounted to 9,071,544,282.27 RMB, compared to 8,732,680,895.93 RMB at the end of 2023[14] - Total assets increased to 16,834,745,203.85 RMB, up from 16,714,285,093.86 RMB in the previous period[15] - Total equity increased to 13,017,525,146.32 RMB from 12,690,009,062.97 RMB[16] - Total assets increased to 15,464,733,902.98 RMB, up from 15,410,450,008.24 RMB in the previous period[23] - Total equity attributable to shareholders rose to 11,945,130,957.33 RMB, up from 11,583,165,376.29 RMB previously[24] Financial Position and Liabilities - The company's monetary funds decreased to 3,635,664,278.51 RMB as of September 30, 2024, from 4,450,600,676.46 RMB at the end of 2023[13] - Tianshi Pharmaceutical Group's accounts receivable increased to 1,040,697,294.55 RMB as of September 30, 2024, from 688,003,223.63 RMB at the end of 2023[14] - The company's inventory decreased slightly to 1,708,285,219.12 RMB as of September 30, 2024, from 1,747,685,395.27 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's long-term equity investments decreased to 1,368,351,638.68 RMB as of September 30, 2024, from 1,415,412,097.78 RMB at the end of 2023[14] - The company's fixed assets decreased to 3,228,253,408.17 RMB as of September 30, 2024, from 3,388,718,651.12 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's development expenditure increased to 1,544,830,366.16 RMB as of September 30, 2024, from 1,452,896,953.08 RMB at the end of 2023[14] - The company's total non-current assets as of September 30, 2024, included 481,957,189.38 RMB in other non-current financial assets, down from 638,217,114.53 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's prepayments increased to 95,274,519.23 RMB as of September 30, 2024, from 65,572,406.23 RMB at the end of 2023[14] - The company's other receivables increased significantly to 86,552,069.72 RMB as of September 30, 2024, from 11,490,057.43 RMB at the end of 2023[14] - Total liabilities decreased to 3,817,220,057.53 RMB from 4,024,276,030.89 RMB in the previous period[16] - Short-term borrowings increased to 993,287,736.04 RMB from 723,051,144.30 RMB[15] - Short-term borrowings increased significantly to 896,570,694.44 RMB, up from 497,476,388.89 RMB previously[23] - Total liabilities decreased to 3,519,602,945.65 RMB, down from 3,827,284,631.95 RMB previously[23] Cash Flow and Investments - Cash received from sales of goods and services in the first three quarters of 2024 was 7,060,063,757.08 RMB, a decrease from 7,318,700,255.57 RMB in the same period of 2023[20] - Net cash flow from operating activities for the first three quarters of 2024 was 1,189,929,757.94 RMB, an increase from 1,089,487,406.49 RMB in the same period of 2023[21] - Cash received from investments in the first three quarters of 2024 was 4,983,417,806.61 RMB, a significant increase from 1,615,886,708.19 RMB in the same period of 2023[21] - Net cash flow from investing activities for the first three quarters of 2024 was -1,499,100,283.76 RMB, a decrease from -298,549,592.91 RMB in the same period of 2023[21] - Net cash flow from financing activities for the first three quarters of 2024 was -866,677,828.49 RMB, a decrease from -158,026,719.99 RMB in the same period of 2023[21] - The company's monetary funds as of September 30, 2024, were 2,235,324,918.20 RMB, a decrease from 3,221,847,242.03 RMB at the end of 2023[22] - The company's total current assets as of September 30, 2024, were 6,147,756,808.30 RMB, slightly increased from 6,128,717,018.14 RMB at the end of 2023[22] - Long-term equity investments as of September 30, 2024, were 6,589,887,702.87 RMB, a slight decrease from 6,629,227,183.33 RMB at the end of 2023[22] - Development expenditure rose to 909,513,693.87 RMB, compared to 828,481,492.63 RMB previously[23] - Cash flow from operating activities for the first three quarters of 2024 was 4,433,623,509.83 RMB, up from 4,365,765,773.15 RMB in the same period last year[27] - Total cash outflow from operating activities was 3,815,438,910.24 RMB, a slight increase from 3,803,717,675.71 RMB in the previous period[28] - Net cash flow from operating activities increased to 618,184,599.59 RMB, up from 562,048,097.44 RMB[28] - Cash inflow from investment activities surged to 5,453,758,056.45 RMB, more than double the previous 2,321,604,557.77 RMB[28] - Cash outflow for investments rose significantly to 6,515,144,853.19 RMB, compared to 2,821,158,230.68 RMB[28] - Net cash flow from investment activities was negative at -1,415,572,973.32 RMB, a larger outflow than the previous -746,101,885.43 RMB[28] - Cash inflow from financing activities decreased to 2,370,688,611.12 RMB, down from 2,759,510,000.00 RMB[28] - Net cash flow from financing activities turned negative at -320,184,257.48 RMB, compared to a positive 1,098,242,648.02 RMB in the previous period[28] - The net increase in cash and cash equivalents was negative at -1,117,572,631.21 RMB, a significant reversal from the previous positive 914,188,860.03 RMB[28] - Ending cash and cash equivalents balance dropped sharply to 777,778,960.59 RMB, down from 3,314,468,818.09 RMB[28] R&D and Sales Expenses - R&D expenses increased to 564,770,536.84 RMB, up from 558,324,364.38 RMB in the previous year[18] - Sales expenses decreased slightly to 2,209,020,849.25 RMB from 2,228,496,399.34 RMB in the previous year[18] - R&D expenses increased to 358,427,153.35 RMB, up from 319,711,789.99 RMB in the same period last year[25] Comprehensive Income and Other Financial Metrics - Comprehensive income for the first three quarters of 2024 reached 810,680,787.13 RMB, a decrease from 908,583,220.60 RMB in the same period of 2023[19] - Other comprehensive income showed a loss of 16,716,055.77 RMB, compared to a loss of 125,431,237.62 RMB in the same period last year[26] - Financial expenses showed a net income of 11,737,585.61 RMB, compared to a net income of 1,968,883.70 RMB in the previous year[18] Business Operations and Acquisitions - Pharmaceutical industrial revenue increased by 2.18%, while pharmaceutical commercial revenue decreased by 25.36%[4] - The company completed the acquisition of Tasly Healthcare Deutschland GmbH in October 2023, leading to adjustments in comparative financial data[4]

证券代码：600535 证券简称：天士力 编号：临 2024-048 号 天士力医药集团股份有限公司 关于公司 2024 年前三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业信 息披露指引第六号——医药制造》及《关于做好上市公司 2024 年前三季度报告 披露工作的通知》相关要求，现将公司 2024 年前三季度主要经营数据披露如下： 报告期内，公司感冒发烧产品收入较上年同期下降 36.42%，主要系报告期内 藿香正气滴丸和穿心莲内酯滴丸销量下降所致。 二、报告期内分地区经营数据 单位：元 币种：人民币 | 地区 | 本期累计主营业务收入 | 上年同期累计主营业务收入 | 增长比例（%） | | --- | --- | --- | --- | | 天津市 | 10,568,184,703.11 | 10,547,491,178.54 | 0.20 | | 陕西省 | 82,308,548.71 | 69,752,254.02 | 18 ...

证券代码：600535 证券简称：天士力 编号：临 2024-047 号 天士力医药集团股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024 年第三次临时股东大会 召开的日期时间：2024 年 11 月 11 日 15 点 30 分 召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限 公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 11 日 至 2024 年 11 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投 ...

证券代码：600535 证券简称：天士力 编号：临 2024-046 号 1 天士力医药集团股份有限公司 关于新增 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 重要内容提示： 本次新增日常关联交易预计事项无需提交股东大会审议。 本次新增日常关联交易符合公司实际情况及经营发展需要，关联交易遵 循了公开、公平、公正的原则，交易定价公允合理，有利于公司的发展，不存在 损害公司和股东利益的行为，不会影响公司的独立性，亦不会对关联方形成依赖。 一、 日常关联交易基本情况 （一） 日常关联交易履行的审议程序 天士力医药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 12 日召 开了第八届董事会第 26 次会议、第八届监事会第 15 次会议，审议通过了《关于 2024 年度预计发生的日常经营性关联交易的议案》，关联董事、监事对该议案进 行了回避表决。该议案于 2024 年 5 月 8 日经公司 2023 年年度股东大会审议批 准，关联股东回避了表决，内容详见公司在上海证券交易所 ...

证券代码：600535 证券简称：天士力 编号：临 2024-044 号 天士力医药集团股份有限公司 经监事会对董事会编制的《2024 年第三季度报告》全文及摘要审慎审核，监 事会一致认为： （1）公司《2024 年第三季度报告》编制和审议程序符合法律、法规、《公司 章程》和公司内部管理制度的各项规定； （2）公司《2024 年第三季度报告》的内容和格式符合中国证监会和上海证 券交易所的各项规定，所包含的信息能从各个方面真实地反映出公司 2024 年第三 季度的经营管理和财务状况； （3）在提出本意见前，监事会未发现参与《2024 年第三季度报告》编制和审 议的人员有违反保密规定的行为。 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《2024 年第 三季度报告》。 第九届监事会第 3 次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届监事会第 3 次会议 通知和会议材料于 2024 年 10 月 15 日向全体监事及公司高级管理人 ...

天士力医药集团股份有限公司 2024 年第三次独立董事专门会议决议 独立董事签名：张斌、王爱俭、韩秀桃 2024 年 10 月 25 日 1 一、审议通过《关于新增 2024 年度日常关联交易预计的议案》 经审查，我们认为：本次新增日常关联交易属于公司正常生产经营活动，关 联交易以市场价格或以成本加合理利润为依据，交易定价客观、公允，体现了公 平合理的市场化原则，不会对公司独立性产生影响，符合公司和全体股东的利益， 不存在损害公司及中小股东利益的情形，一致同意将该议案提交公司董事会审议。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 天士力医药集团股份限公司（以下简称"公司"）2024 年第三次独立董事专 门会议于 2024 年 10 月 25 日以通讯方式召开。本次会议由全体独立董事共同推 举张斌先生召集并主持。本次会议应到独立董事 3 人，实到独立董事 3 人。本次 会议的召开符合《上市公司独立董事管理办法》、《公司章程》、《独立董事工作制 度》等有关规定，经与会独立董事审议形成决议如下： ...

2024 年第三季度利润分配预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 重要内容提示: 证券代码：600535 证券简称：天士力 编号：临 2024-045 号 每股分配比例：每10股分派现金股利0.70元（含税）。 1 公司于 2024 年 10 月 25 日召开了第九届董事会第 4 次会议，会议审议并通 过了《2024 年第三季度利润分配预案》，表决情况为：有效表决票 9 票，其中同 意 9 票、反对 0 票、弃权 0 票。本次利润分配方案尚需提交 2024 年第三次临时 股东大会审议。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 截至 2024 年 9 月 30 日，天士力医药集团股份有限公司（以下简称"公司"、 "上市公司"）母公司期末可供分配利润为人民币 7,323,888,695 ...